Evidence map›Paper›PMID 28624395›Full record

ArticleJACC. Cardiovascular imaging2018

Statin Trials, Cardiovascular Events, and Coronary Artery Calcification: Implications for a Trial-Based Approach to Statin Therapy in MESA.

Martin Bødtker Mortensen, Erling Falk, Dong Li, Khurram Nasir, Michael J Blaha, Veit Sandfort, Carlos Jose Rodriguez, Pamela Ouyang, Matthew Budoff

Registry-linked trialAbstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in JACC. Cardiovascular imaging, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04977089 (Study of Lipid Profile of Patients With Chronic Coronary Syndromes at Sohag University Hospital), which is not on this map. Cited by 32 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed, 2 pooled it
10.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04977089 unknown statusnot on this mapstarted 2020, after this paper: background citation

Study of Lipid Profile of Patients With Chronic Coronary Syndromes at Sohag University Hospital

TypeobservationalSponsorSohag UniversityRan2020 to 2021Enrolled100ConditionsIschemic Heart Disease, DyslipidemiasArmslipid profile test .
3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 2 syntheses or guidelines pooled it, 86 citations in OpenAlex.

  1. Preoperative statin therapy for adults undergoing cardiac surgery.The Cochrane database of systematic reviews · 2024
    Pooled it
  2. Pooled it
  3. Article
  4. Review
  5. Review
  6. CT coronary angiography in the lipid clinic: a pilot study and lipidologist survey.The international journal of cardiovascular imaging · 2025
    Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Subclinical cardiovascular disease and utility of coronary artery calcium score.International journal of cardiology. Heart & vasculature · 2021
    Review
  16. Review
  17. Review
  18. Article
  19. Review
  20. Egyptian practical guidance in lipid management 2020.The Egyptian heart journal : (EHJ) : official bulletin of the Egyptian Society of Cardiology · 2021
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 6 institutions in 2 countries.

Martin Bødtker MortensenDepartment of Cardiology, Aarhus University Hospital, Aarhus, Denmark. Electronic address: martin.bodtker.mortensen@clin.au.dk.
Erling FalkDepartment of Cardiology, Aarhus University Hospital, Aarhus, Denmark.
Dong LiDivision of Cardiology, Los Angeles Biomedical Research Institute at Harbor-UCLA, University of California Los Angeles, Torrance, California.
Khurram NasirCenter for Healthcare Advancement and Outcomes, Baptist Health South Florida, Miami, Florida; Department of Epidemiology, Robert Stempel College of Public Health and Department of Medicine, Herbert Wertheim College of Medicine, Florida International University, Florida; The Johns Hopkins Ciccarone Center for the Prevention of Heart Disease, Baltimore, Maryland.
Michael J BlahaThe Johns Hopkins Ciccarone Center for the Prevention of Heart Disease, Baltimore, Maryland.
Veit SandfortRadiology and Imaging Sciences, National Institutes of Health, Bethesda, Maryland.
Carlos Jose RodriguezDivision of Public Health Sciences, Department of Epidemiology and Prevention, Wake Forest School of Medicine, Winston-Salem, North Carolina.
Pamela OuyangThe John Hopkins University School of Medicine, Baltimore, Maryland.
Matthew BudoffDivision of Cardiology, Los Angeles Biomedical Research Institute at Harbor-UCLA, University of California Los Angeles, Torrance, California.
Aarhus University Hospital · DKThe Lundquist Institute · USBaptist Hospital of Miami · USJohns Hopkins University · USNational Institutes of Health · USWake Forest University · US

Funding

Institute for Clinical and Translational ResearchUL1TR001079 · NCATS · JOHNS HOPKINS UNIVERSITY · PI FORD, DANIEL ERNEST · 2013 to 2017
$60.1M
Clinical and Translational Science AwardUL1TR000040 · NCATS · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI GINSBERG, HENRY N · 2012 to 2015
$26.2M
Cigarette Smoke and Susceptibility to Influenza InfectionR01HL095163 · NHLBI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI JASPERS, ILONA, NOAH, TERRY L · 2009 to 2013
$2.0M
Adjunctive Use of Apyrase to Fibrinolytic TherapyR44HL095169 · NHLBI · APT THERAPEUTICS, INC. · PI CHEN, RIDONG · 2012 to 2013
$1.3M
SUBCLINICAL CARDIOVASCULAR DISEASE STUDYN01HC095166 · HC · UNIVERSITY OF VERMONT &ST AGRIC COLLEGE · PI TRACY, RUSSELL P · 1999 to 2001
$758k
SUBCLINICAL CARDIOVASCULAR DISEASE STUDY-FIELD CENTERN01HC095162 · HC · JOHNS HOPKINS UNIVERSITY · PI SZKLO, MOYSES A · 1999 to 2000
$694k
SUBCLINICAL CARDIOVASCULAR DISEASE STUDY--FIELD CENTERN01HC095161 · HC · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI SHEA, STEVEN · 1999 to 2001
$642k
SUBCLINICAL CARDIOVASCULAR DISEASE STUDY--FIELD CENTERN01HC095165 · HC · WAKE FOREST UNIVERSITY · PI BURKE, GREGORY L · 1999 to 2001
$616k
SUBCLINICAL CARDIOVASCULAR DISEASE STUDY--FIELD CENTERN01HC095160 · HC · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI SAAD, MOHAMMED F · 1999 to 2001
$592k
SUBCLINICAL CARDIOVASCULAR DISEASE STUDY-FIELD CENTERN01HC095164 · HC · NORTHWESTERN UNIVERSITY · PI LIU, KIANG JOHN · 1999 to 2001
$511k
SUBCLINICAL CARDIOVASCULAR DISEASE STUDY--FIELD CENTERN01HC095163 · HC · UNIVERSITY OF MINNESOTA TWIN CITIES · PI FOLSOM, AARON R · 1999 to 2001
$443k
Enhancing immune reconstitution after implantation of postnatal allogeneic thymusR21HL095165 · NHLBI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI CROOKS, GAY M · 2008 to 2009
$440k
NCATS NIH HHS UL1 TR000040NCATS NIH HHS UL1 TR001079NHLBI NIH HHS HHSN268201500003CNHLBI NIH HHS HHSN268201500003INHLBI NIH HHS N01 HC095159NHLBI NIH HHS N01 HC095160NHLBI NIH HHS N01 HC095161NHLBI NIH HHS N01 HC095162NHLBI NIH HHS N01 HC095163NHLBI NIH HHS N01 HC095164NHLBI NIH HHS N01 HC095165NHLBI NIH HHS N01 HC095166NHLBI NIH HHS N01 HC095167NHLBI NIH HHS N01 HC095168NHLBI NIH HHS N01 HC095169
6 · The paper itself

Abstract

objectivesThis study sought to determine whether coronary artery calcium (CAC) could be used to optimize statin allocation among individuals for whom trial-based evidence supports efficacy of statin therapy.

backgroundRecently, allocation of statins was proposed for primary prevention of atherosclerotic cardiovascular disease (ASCVD) based on proven efficacy from randomized controlled trials (RCTs) of statin therapy, a so-called trial-based approach.

methodsThe study used data from MESA (Multi-Ethnic Study of Atherosclerosis) with 5,600 men and women, 45 to 84 years of age, and free of clinical ASCVD, lipid-lowering therapy, or missing information for risk factors at baseline examination.

resultsDuring 10 years' follow-up, 354 ASCVD and 219 hard coronary heart disease (CHD) events occurred. Based on enrollment criteria for 7 RCTs of statin therapy in primary prevention, 73% of MESA participants (91% of those >55 years of age) were eligible for statin therapy according to a trial-based approach. Among those individuals, CAC = 0 was common (44%) and was associated with low rates of ASCVD and CHD (3.9 and 1.7, respectively, per 1,000 person-years). There was a graded increase in event rates with increasing CAC score, and in individuals with CAC >100 (27% of participants) the rates of ASCVD and CHD were 18.9 and 12.7, respectively. Consequently, the estimated number needed to treat (NNT) in 10 years to prevent 1 event varied greatly according to CAC score. For ASCVD events, the NNT was 87 for CAC = 0 and 19 for CAC >100. For CHD events, the NNT was 197 for CAC = 0 and 28 for CAC >100.

conclusionsMost MESA participants qualified for trial-based primary prevention with statins. Among the individuals for whom trial-based evidence supports efficacy of statin therapy, CAC = 0 and CAC >100 were common and associated with low and high cardiovascular risks, respectively. This information may guide shared decision making aimed at targeting evidence-based statins to those who are likely to benefit the most.

Indexed as

Randomized Controlled Trials as TopicAgedAged, 80 and overClinical Decision-MakingCoronary AngiographyCoronary Artery DiseaseDyslipidemiasEvidence-Based MedicineFemaleHumansHydroxymethylglutaryl-CoA Reductase InhibitorsMaleMiddle AgedPatient SelectionPrimary PreventionRisk FactorsHydroxymethylglutaryl-CoA Reductase Inhibitorscardiovascular diseaseguidelinelipoproteinsprimary preventionstatin

Identifiers

PMID28624395
PMCPMC5723240
OpenAlexW2730247497

What OpenQuestion holds

Texttitle and abstract
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.